Bavarian Nordic, Roche to test bladder cancer combo
Roche and Bavarian Nordic have unveiled plans to assess the former’s anti-PD-L1 antibody Tecentriq in combination with the latter’s cancer vaccine candidate CV301 in bladder cancer.
Read More
Tag: CV301
BMS to supply Opdivo for Bavarian Nordic trial
Bristol-Myers Squibb has agreed to supply Bavarian Nordic with Opdivo for use in a clinical trial assessing the immunotherapy in combination with experimental drug CV301.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
